Fructose 5-dehydrogenase [NADP(+)] Antibody

What is Fructose 5-dehydrogenase [NADP(+)] and why is it important in metabolism research?

Fructose 5-dehydrogenase [NADP(+)] (EC 1.1.1.124) is an oxidoreductase enzyme that catalyzes the conversion of D-fructose and NADP+ to 5-dehydro-D-fructose, NADPH, and H+. The enzyme belongs to the family of oxidoreductases acting on CH-OH donor groups with NADP+ as an acceptor . Its systematic name is D-fructose:NADP+ 5-oxidoreductase. This enzyme is critical for studying fructose metabolism pathways, particularly in contexts where alternative sugar metabolism becomes relevant, such as in cancer research and metabolic disorders.

How do I determine the appropriate antibody concentration for detecting Fructose 5-dehydrogenase in Western blotting experiments?

For optimal Western blotting results, perform an antibody titration experiment using a positive control sample with known Fructose 5-dehydrogenase expression. Begin with a 1:500 to 1:1000 dilution range and expand to 1:2000 or 1:5000 if needed. Prepare sample lysates from tissues with known enzyme expression (such as small intestine or kidney tissues) alongside negative controls . When analyzing your titration results, select the highest dilution that provides a clear specific band at the expected molecular weight (~37-45 kDa) with minimal background. For quantitative studies, ensure the signal falls within the linear detection range of your imaging system.

What tissues are most appropriate for positive controls when validating a Fructose 5-dehydrogenase antibody?

The small intestine serves as the primary positive control tissue for Fructose 5-dehydrogenase antibody validation, as it shows the highest expression of related fructose metabolism enzymes. Kidney tissues also express measurable levels and can serve as secondary positive controls . For cellular models, intestinal epithelial cell lines are preferred. When validating antibody specificity, parallel testing with Glut5 knockout models or tissues can provide valuable negative controls. In experimental design, include both high-expressing and low-expressing tissues to demonstrate the antibody's dynamic range of detection capability.

How can Fructose 5-dehydrogenase antibodies be utilized to investigate the relationship between fructose metabolism and cancer progression?

To investigate connections between fructose metabolism and cancer progression, design a multi-faceted approach using Fructose 5-dehydrogenase antibodies alongside other fructose pathway markers. First, establish baseline expression profiles in normal versus malignant tissues using immunohistochemistry on tissue microarrays with appropriate antibody dilutions . For mechanistic studies, combine genetic manipulation (siRNA/shRNA targeting Fructose 5-dehydrogenase) with metabolic assessments (ATP production, lactate measurement, and fructose consumption rates) in cancer cell lines. Co-immunoprecipitation experiments using the validated antibody can reveal protein-protein interactions within the metabolic complex. For in vivo studies, xenograft models with manipulated enzyme expression followed by immunohistochemical analysis can correlate tumor growth patterns with enzyme activity and localization .

What methodological approaches are recommended for studying Fructose 5-dehydrogenase regulatory mechanisms in response to dietary interventions?

For studying regulatory mechanisms of Fructose 5-dehydrogenase in response to dietary interventions, implement a comprehensive experimental design combining in vivo and ex vivo approaches. Begin with dietary manipulation studies in animal models (e.g., high fructose diet vs. control diet) for 7-14 days . Collect intestinal segments at multiple timepoints for protein analysis using the antibody in Western blots and immunofluorescence to track both expression levels and subcellular localization changes. Supplement protein detection with mRNA analysis using qRT-PCR to distinguish transcriptional from post-transcriptional regulation. For mechanistic insights, perform chromatin immunoprecipitation (ChIP) assays to identify transcription factors binding to the promoter region in response to dietary changes. Use intestinal organoids as an ex vivo model to manipulate nutrient conditions in a controlled environment while maintaining physiological cell polarization.

How can I design experiments to investigate potential cross-reactivity between Fructose 5-dehydrogenase and structurally similar enzymes using antibody-based approaches?

To assess antibody cross-reactivity with structurally similar enzymes to Fructose 5-dehydrogenase, implement a strategic experimental approach. First, perform comprehensive sequence alignment analysis to identify enzymes with similar epitope regions, particularly other dehydrogenases in the oxidoreductase family. Prepare recombinant protein panels including Fructose 5-dehydrogenase and at least 3-5 structurally similar enzymes. Conduct comparative Western blots using consistent protein loading (verified by total protein staining) to evaluate binding specificity. For definitive validation, use genetic knockout or knockdown models (e.g., CRISPR-Cas9 edited cell lines) to confirm signal elimination when the target enzyme is absent . Immunoprecipitation followed by mass spectrometry can identify any unintended targets. Finally, perform competition assays using purified recombinant proteins to quantitatively measure binding affinities and potential cross-reactivity.

What are the optimal tissue fixation and antigen retrieval protocols for immunohistochemical detection of Fructose 5-dehydrogenase?

For optimal immunohistochemical detection of Fructose 5-dehydrogenase, tissue fixation and antigen retrieval must be carefully optimized. Fresh tissues should be fixed in 10% neutral-buffered formalin for 24 hours (avoid over-fixation which may mask epitopes). For paraffin embedding, process tissues using standard protocols with dehydration through graded ethanol series. Prepare sections at 4-5 μm thickness on positively charged slides. For antigen retrieval, heat-induced epitope retrieval (HIER) using citrate buffer (pH 6.0) at 95-98°C for 20 minutes typically yields optimal results . Following retrieval, block endogenous peroxidase activity using hydrogen peroxide, then block non-specific binding with 1-5% BSA or commercial blocking reagents for 25-30 minutes at room temperature. Primary antibody incubation should be performed overnight at 4°C in a humidified chamber with optimized dilution (typically 1:100 to 1:500), followed by appropriate secondary antibody and visualization systems .

How can I quantitatively assess Fructose 5-dehydrogenase enzyme activity in tissue samples alongside antibody-based protein detection?

To comprehensively characterize Fructose 5-dehydrogenase, combine antibody-based protein detection with enzyme activity assays. First, prepare tissue homogenates in non-denaturing buffers that preserve enzyme activity. Split each sample for parallel analysis: (1) For activity assays, measure the conversion rate of D-fructose and NADP+ to 5-dehydro-D-fructose and NADPH spectrophotometrically by monitoring NADPH production at 340 nm under optimized temperature (37°C) and pH (7.4) conditions . (2) For protein quantification, perform Western blotting with the validated antibody. To ensure correlation between protein levels and activity, normalize both measurements to total protein and plot the relationship. For tissue-specific activity mapping, combine enzyme histochemistry (using tetrazolium salts that form colored precipitates in the presence of NADPH) with immunohistochemistry on serial sections to visualize both protein localization and functional activity.

What immunofluorescence techniques provide the best results for subcellular localization studies of Fructose 5-dehydrogenase in polarized epithelial cells?

For optimal subcellular localization of Fructose 5-dehydrogenase in polarized epithelial cells, implement a refined immunofluorescence protocol. Begin with either properly oriented frozen sections (8-10 μm) or formalin-fixed paraffin-embedded tissues subjected to appropriate antigen retrieval. For cell culture models, grow cells on permeable supports or chamber slides to maintain polarization. Fix samples with 4% paraformaldehyde for 15 minutes followed by permeabilization with 0.2% Triton X-100 for 10 minutes . Block with 5% normal serum from the secondary antibody host species for 1 hour. Apply primary antibody at optimized dilution (1:100-1:500) overnight at 4°C, followed by fluorescently-labeled secondary antibody. For precise subcellular localization, perform co-staining with established markers: E-cadherin for basolateral membranes, GLUT5 for apical membranes in intestinal cells, and organelle markers as needed . Use confocal microscopy with z-stack acquisition (0.5-1.0 μm steps) to generate 3D reconstructions that definitively establish membrane domain localization.

How do I address inconsistent Western blot results when detecting Fructose 5-dehydrogenase across different tissue samples?

When encountering inconsistent Western blot results for Fructose 5-dehydrogenase across tissue samples, implement a systematic troubleshooting approach. First, evaluate sample preparation: ensure consistent protein extraction using buffer systems that account for membrane-association properties of the enzyme. Verify protein integrity by Ponceau S staining and normalize loading using total protein quantification rather than single housekeeping proteins. For tissue-specific optimization, adjust extraction buffers accordingly (e.g., higher detergent concentrations for intestinal samples) . Test multiple antibody dilutions and incubation conditions using a dilution series matrix. If tissue-specific post-translational modifications affect antibody recognition, consider using alternative epitope-targeted antibodies. For quantitative comparisons, implement technical triplicates and standardize exposure times. If expression levels vary dramatically between tissues, prepare separate blots with appropriate exposure times for high and low expressing samples, using a common reference sample on both blots for normalization.

What approaches can resolve discrepancies between mRNA expression and protein detection results for Fructose 5-dehydrogenase?

To resolve discrepancies between mRNA and protein levels of Fructose 5-dehydrogenase, implement a comprehensive analysis workflow. First, validate both methodologies independently: for qRT-PCR, design multiple primer pairs targeting different exons and confirm specificity through melt curve analysis and sequencing; for protein detection, validate antibody specificity using positive and negative controls . Next, investigate potential biological explanations: (1) Assess protein stability through cycloheximide chase experiments to determine protein half-life; (2) Evaluate post-transcriptional regulation by analyzing microRNA binding sites and performing reporter assays; (3) Examine post-translational modifications that might affect antibody epitope recognition using phosphatase/deglycosylation treatments before Western blotting; (4) Consider translational efficiency through polysome profiling. Finally, expand time-course analysis to capture potential temporal delays between transcription and translation. Plotting mRNA versus protein levels across multiple experimental conditions can reveal consistent relationships despite absolute level differences.

How should I interpret and validate unexpected immunolocalization patterns of Fructose 5-dehydrogenase in diseased tissues?

When encountering unexpected immunolocalization patterns of Fructose 5-dehydrogenase in diseased tissues, implement a rigorous validation strategy. First, confirm antibody specificity in the disease context using multiple approaches: (1) Test multiple antibodies targeting different epitopes; (2) Perform peptide competition assays to verify binding specificity; (3) Include appropriate positive and negative control tissues in each experiment . Next, characterize the unexpected pattern using high-resolution confocal microscopy and co-localization with organelle-specific markers to precisely define the altered subcellular distribution. To validate the biological significance, correlate localization changes with functional outcomes through enzyme activity assays on subcellular fractions. Perform additional validation using complementary techniques such as in situ hybridization for mRNA localization or proximity ligation assays to confirm protein interactions in the new location. Finally, investigate potential disease-specific modifications (phosphorylation, glycosylation) that might affect localization through specific inhibitor treatments or site-directed mutagenesis in cellular models.

How can Fructose 5-dehydrogenase antibodies be utilized in co-immunoprecipitation studies to identify novel protein interactions in the fructose metabolism pathway?

For co-immunoprecipitation (co-IP) studies to identify novel Fructose 5-dehydrogenase protein interactions, implement a multi-phase experimental approach. Begin with antibody validation specifically for immunoprecipitation by confirming the antibody can effectively pull down the target protein from native lysates. Prepare tissue or cell lysates using gentle non-denaturing buffers (typically containing 0.5-1% NP-40 or Triton X-100) that preserve protein-protein interactions. For the co-IP procedure, pre-clear lysates with protein A/G beads before incubation with the validated antibody at optimized concentrations (typically 2-5 μg antibody per mg protein) . Include appropriate negative controls (non-specific IgG from the same species). After immunoprecipitation, analyze by both targeted Western blotting for suspected interactors and unbiased mass spectrometry to identify novel binding partners. Validate promising interactions through reciprocal co-IPs and proximity ligation assays in intact cells. For functional validation, implement genetic manipulation of identified partners and assess impact on fructose metabolism using enzyme activity assays and metabolomic profiling.

What is the optimal approach for comparing expression and localization patterns of Fructose 5-dehydrogenase and GLUT5 transporters in intestinal tissue?

To optimally compare Fructose 5-dehydrogenase and GLUT5 expression patterns in intestinal tissue, design a comprehensive multi-method approach. Begin with dual immunofluorescence staining on properly oriented intestinal sections, using validated antibodies with distinct fluorophores and careful controls to prevent spectral overlap . Perform z-stack confocal microscopy to generate three-dimensional reconstructions of transporter distributions across the villus-crypt axis. Complement imaging with quantitative protein analysis via Western blotting of samples fractionated by the brush border isolation technique to separate apical from basolateral membranes. For functional correlation, implement ex vivo intestinal sac models to measure fructose uptake and metabolism while manipulating expression through genetic or pharmacological approaches. To assess adaptive regulation, compare expression patterns under various conditions (fasting, high-fructose diet, diabetes models) with parallel analysis of both transporters . Create quantitative heat maps of expression intensity along the intestinal longitudinal axis (duodenum to ileum) to identify regions of co-expression or differential regulation.

How can multiplexed immunoassays be developed to simultaneously detect multiple enzymes in the fructose metabolism pathway including Fructose 5-dehydrogenase?

To develop multiplexed immunoassays for simultaneous detection of multiple fructose metabolism enzymes, implement a systematic optimization strategy. Begin with antibody validation for each target enzyme (Fructose 5-dehydrogenase, ketohexokinase, aldolase B, and GLUT5) through single-plex Western blots and immunohistochemistry to confirm specificity and optimal working conditions . For fluorescence-based multiplexing, select primary antibodies from different host species or use directly conjugated primary antibodies with spectrally distinct fluorophores. Optimize antibody panels through titration matrices to identify concentrations that provide equivalent signal intensities across targets. Implement tyramide signal amplification for targets with low expression levels. For automated quantitative analysis, develop computational image analysis workflows using machine learning algorithms to segment subcellular compartments and quantify co-localization coefficients. Validate the multiplexed assay against single-plex results using correlation analysis. For absolute quantification, incorporate internal calibration standards using recombinant proteins. This approach enables comprehensive pathway analysis while preserving spatial context and reducing sample requirements compared to traditional methods.